Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. Its product pipeline include Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Can-Fite Biopharma Ltd. CANF, -2.05% soared 18% in active premarket trading Tuesday, after the Israel-based drug development company announced a collaboration agreement with Israeli medical cannabis company Univo Pharmaceuticals Ltd.

Can-Fite's stock soars on heavy volume after collaboration deal with cannabis company Univo

Can-Fite BioPharma (NYSE: CANF) announced a new deal with Kyongbo Pharm to distribute the drug Piclidenoson for Psoriasis in South Korea, receiving $4 million payment upfront.

Can-Fite BioPharma Reports $4M Deal With Kyongbo Pharm

Can-Fite BioPharma (NYSE: CANF) 6-K shows the company filed an appeal with the Supreme Court of Israel of a decision related to the convening of a special shareholder meeting to replace directors.

Can-Fite BioPharma Appeals Lawsuit Against Venture Capital Firm

Can-Fite (CANF) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Can-Fite (CANF) Rating Upgrade to Strong Buy

In Q1/2019, Can-Fite reported that Namodenoson didn’t achieve the primary endpoint in the Phase 2 liver cancer study, but achieved superiority in median overall survival in a subgroup.

Can-Fite And Namodenoson In Advanced Liver Cancer: The Innovative Approach

Shares of the biotech Can-Fite Biopharma Ltd were skyrocketing Monday after an abstract describing data from the company's liver cancer study of the drug namodenoson was selected by the International Liver Cancer Association conference.

Can-Fite Abstract Selected For Liver Conference, Stock Jumps More Than 60%

News for Can-Fite BioPharma Ltd. Stock (CANF)